Early Detection of Complications During Immunotherapy for Haematological Malignancy

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions
Hematologic CancerCRS - Cytokine Release Syndrome
Interventions
DEVICE

WARD

Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.

Trial Locations (1)

2100

RECRUITING

Rigshospitalet, Copenhagen O

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER